MacroGenics Current Deferred Revenue vs Long Term Investments Analysis

MGNX Stock

USD 15.67 0.45 2.96%

MacroGenics financial indicator trend analysis is infinitely more than just investigating MacroGenics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MacroGenics is a good investment. Please check the relationship between MacroGenics Current Deferred Revenue and its Long Term Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

Current Deferred Revenue vs Long Term Investments

Current Deferred Revenue vs Long Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MacroGenics Current Deferred Revenue account and Long Term Investments. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between MacroGenics' Current Deferred Revenue and Long Term Investments is -0.09. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Long Term Investments in the same time period over historical financial statements of MacroGenics, assuming nothing else is changed. The correlation between historical values of MacroGenics' Current Deferred Revenue and Long Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of MacroGenics are associated (or correlated) with its Long Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Investments has no effect on the direction of Current Deferred Revenue i.e., MacroGenics' Current Deferred Revenue and Long Term Investments go up and down completely randomly.

Correlation Coefficient

-0.09

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Long Term Investments

Long Term Investments is an item on the asset side of MacroGenics balance sheet that represents investments MacroGenics intends to hold for over a year. MacroGenics long term investments may include different instruments such as stocks, bonds, real estate and cash.

Most indicators from MacroGenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.Enterprise Value is likely to rise to about 442.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 37 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	275.8M	266.0M	226.4M	181.8M
Cost Of Revenue	2.7M	7.4M	619K	588.1K

Total Operating Expenses Cost Of Revenue

MacroGenics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.31	0.38	0.97	-0.24	0.78	-0.33	-0.58	-0.53	-0.13	0.74	0.8	0.41	0.23	0.95	0.39	0.81	0.74	0.08	0.64	0.76	0.21	0.52	0.99	-0.28	0.84
Other Current Liab	0.31		0.3	0.24	0.13	0.31	-0.02	0.0	-0.26	0.2	0.08	0.32	0.14	0.09	0.26	0.18	0.15	0.49	0.21	0.26	0.29	0.3	0.25	0.29	-1.0	0.15
Total Current Liabilities	0.38	0.3		0.2	0.01	0.67	0.24	-0.02	-0.67	0.64	0.17	0.67	0.38	0.61	0.16	0.45	0.54	0.67	0.29	0.71	0.66	0.7	0.68	0.27	-0.28	0.54
Total Stockholder Equity	0.97	0.24	0.2		-0.39	0.62	-0.5	-0.66	-0.33	-0.22	0.78	0.68	0.43	0.19	0.98	0.23	0.68	0.56	-0.12	0.52	0.59	-0.04	0.37	0.98	-0.21	0.71
Other Liab	-0.24	0.13	0.01	-0.39		0.1	0.64	0.36	-0.33	-0.14	-0.23	-0.12	-0.73	-0.46	-0.31	0.37	-0.02	0.09	0.84	-0.3	0.06	0.56	0.24	-0.25	-0.16	-0.05
Property Plant And Equipment Net	0.78	0.31	0.67	0.62	0.1		0.15	-0.35	-0.72	-0.04	0.54	0.95	0.31	0.14	0.56	0.75	0.82	0.84	0.41	0.65	0.84	0.65	0.58	0.68	-0.29	0.83
Current Deferred Revenue	-0.33	-0.02	0.24	-0.5	0.64	0.15		0.45	-0.36	0.23	-0.38	0.01	-0.46	-0.02	-0.54	0.67	0.04	0.18	0.58	0.02	0.18	0.62	-0.05	-0.39	-0.01	0.04
Net Debt	-0.58	0.0	-0.02	-0.66	0.36	-0.35	0.45		-0.2	0.43	-0.93	-0.31	-0.18	0.05	-0.63	-0.12	-0.22	-0.05	0.42	-0.05	-0.08	0.27	0.06	-0.61	-0.02	-0.25
Retained Earnings	-0.53	-0.26	-0.67	-0.33	-0.33	-0.72	-0.36	-0.2		-0.3	-0.12	-0.72	-0.22	-0.35	-0.31	-0.62	-0.83	-0.89	-0.75	-0.78	-0.91	-0.81	-0.82	-0.44	0.26	-0.83
Accounts Payable	-0.13	0.2	0.64	-0.22	-0.14	-0.04	0.23	0.43	-0.3		-0.38	0.06	0.31	0.69	-0.22	-0.04	0.02	0.22	0.04	0.44	0.2	0.33	0.28	-0.17	-0.2	0.02
Cash	0.74	0.08	0.17	0.78	-0.23	0.54	-0.38	-0.93	-0.12	-0.38		0.51	0.26	0.0	0.74	0.27	0.45	0.29	-0.14	0.27	0.32	-0.08	0.23	0.76	-0.05	0.48
Non Current Assets Total	0.8	0.32	0.67	0.68	-0.12	0.95	0.01	-0.31	-0.72	0.06	0.51		0.56	0.25	0.59	0.66	0.83	0.85	0.28	0.79	0.85	0.54	0.57	0.7	-0.3	0.85
Non Currrent Assets Other	0.41	0.14	0.38	0.43	-0.73	0.31	-0.46	-0.18	-0.22	0.31	0.26	0.56		0.43	0.32	-0.05	0.35	0.35	-0.31	0.68	0.36	-0.04	0.22	0.34	-0.12	0.38
Other Assets	0.23	0.09	0.61	0.19	-0.46	0.14	-0.02	0.05	-0.35	0.69	0.0	0.25	0.43		0.16	-0.02	0.33	0.38	-0.2	0.67	0.4	0.14	0.39	0.2	-0.08	0.35
Cash And Short Term Investments	0.95	0.26	0.16	0.98	-0.31	0.56	-0.54	-0.63	-0.31	-0.22	0.74	0.59	0.32	0.16		0.13	0.66	0.54	-0.07	0.45	0.56	-0.03	0.42	0.98	-0.23	0.68
Net Receivables	0.39	0.18	0.45	0.23	0.37	0.75	0.67	-0.12	-0.62	-0.04	0.27	0.66	-0.05	-0.02	0.13		0.55	0.62	0.52	0.44	0.63	0.66	0.2	0.3	-0.19	0.58
Common Stock Total Equity	0.81	0.15	0.54	0.68	-0.02	0.82	0.04	-0.22	-0.83	0.02	0.45	0.83	0.35	0.33	0.66	0.55		0.91	0.4	0.81	0.96	0.59	0.67	0.76	-0.13	0.99
Common Stock Shares Outstanding	0.74	0.49	0.67	0.56	0.09	0.84	0.18	-0.05	-0.89	0.22	0.29	0.85	0.35	0.38	0.54	0.62	0.91		0.51	0.85	0.97	0.73	0.69	0.66	-0.48	0.91
Non Current Liabilities Total	0.08	0.21	0.29	-0.12	0.84	0.41	0.58	0.42	-0.75	0.04	-0.14	0.28	-0.31	-0.2	-0.07	0.52	0.4	0.51		0.2	0.49	0.78	0.59	0.03	-0.23	0.38
Other Current Assets	0.64	0.26	0.71	0.52	-0.3	0.65	0.02	-0.05	-0.78	0.44	0.27	0.79	0.68	0.67	0.45	0.44	0.81	0.85	0.2		0.87	0.49	0.62	0.56	-0.24	0.83
Other Stockholder Equity	0.76	0.29	0.66	0.59	0.06	0.84	0.18	-0.08	-0.91	0.2	0.32	0.85	0.36	0.4	0.56	0.63	0.96	0.97	0.49	0.87		0.72	0.7	0.69	-0.28	0.96
Total Liab	0.21	0.3	0.7	-0.04	0.56	0.65	0.62	0.27	-0.81	0.33	-0.08	0.54	-0.04	0.14	-0.03	0.66	0.59	0.73	0.78	0.49	0.72		0.59	0.11	-0.3	0.56
Property Plant And Equipment Gross	0.52	0.25	0.68	0.37	0.24	0.58	-0.05	0.06	-0.82	0.28	0.23	0.57	0.22	0.39	0.42	0.2	0.67	0.69	0.59	0.62	0.7	0.59		0.47	-0.23	0.66
Total Current Assets	0.99	0.29	0.27	0.98	-0.25	0.68	-0.39	-0.61	-0.44	-0.17	0.76	0.7	0.34	0.2	0.98	0.3	0.76	0.66	0.03	0.56	0.69	0.11	0.47		-0.26	0.78
Short Term Debt	-0.28	-1.0	-0.28	-0.21	-0.16	-0.29	-0.01	-0.02	0.26	-0.2	-0.05	-0.3	-0.12	-0.08	-0.23	-0.19	-0.13	-0.48	-0.23	-0.24	-0.28	-0.3	-0.23	-0.26		-0.13
Common Stock	0.84	0.15	0.54	0.71	-0.05	0.83	0.04	-0.25	-0.83	0.02	0.48	0.85	0.38	0.35	0.68	0.58	0.99	0.91	0.38	0.83	0.96	0.56	0.66	0.78	-0.13

Click cells to compare fundamentals

MacroGenics Account Relationship Matchups

MacroGenics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Other Current Liab	27.1M	27.3M	33.8M	(30.5M)	24.2M	25.5M
Total Current Liabilities	45.2M	50.7M	74.6M	48.6M	56.1M	47.8M
Total Stockholder Equity	230.6M	295.9M	239.6M	142.0M	152.6M	199.6M
Other Liab	9.2M	6.9M	258K	59.7M	53.8M	56.5M
Property Plant And Equipment Net	48.2M	42.2M	37.7M	56.9M	45.7M	32.9M
Current Deferred Revenue	10.7M	11.4M	20.6M	69.5M	21.7M	22.3M
Net Debt	(95.9M)	(151.9M)	(98.0M)	(74.1M)	(67.0M)	(70.3M)
Retained Earnings	(642.1M)	(771.8M)	(973.9M)	(1.1B)	(1.1B)	(1.0B)
Accounts Payable	4.3M	8.0M	15.5M	4.9M	6.4M	6.1M
Cash	126.5M	181.1M	123.5M	108.9M	101.0M	146.4M
Non Current Assets Total	72.7M	66.1M	55.7M	58.3M	47.1M	40.8M
Non Currrent Assets Other	24.5M	23.9M	18.0M	(7.7M)	1.4M	1.3M
Other Assets	4.3M	23.9M	335.2M	1.4M	1.6M	1.5M
Cash And Short Term Investments	215.8M	272.5M	243.6M	154.3M	229.8M	224.7M
Net Receivables	12.7M	23.1M	10.4M	56.2M	10.4M	14.4M
Common Stock Total Equity	490K	562K	613K	617K	709.6K	396.0K
Common Stock Shares Outstanding	48.1M	52.4M	59.9M	61.4M	61.9M	42.1M
Liabilities And Stockholders Equity	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Non Current Liabilities Total	36.7M	32.2M	21.0M	89.8M	89.7M	94.2M
Other Current Assets	11.3M	17.0M	21.2M	10.2M	9.9M	7.7M
Other Stockholder Equity	872.2M	1.1B	1.2B	1.2B	1.3B	774.0M
Total Liab	81.9M	82.9M	95.6M	138.5M	145.8M	87.9M
Property Plant And Equipment Gross	48.2M	42.2M	110.5M	29.6M	134.1M	140.8M
Total Current Assets	239.8M	312.6M	279.6M	222.2M	251.3M	246.7M
Accumulated Other Comprehensive Income	(61K)	(3K)	16K	(7K)	(6K)	(6.3K)
Short Term Debt	3.0M	4.0M	4.7M	4.7M	3.8M	3.6M
Common Stock	490K	562K	613K	617K	621K	418.1K
Property Plant Equipment	68.4M	42.2M	37.7M	29.6M	34.0M	30.8M
Net Tangible Assets	230.6M	295.9M	239.6M	142.0M	163.3M	245.6M
Short Term Investments	89.3M	91.4M	120.1M	45.5M	128.8M	91.7M
Capital Surpluse	872.2M	1.1B	1.2B	1.2B	1.4B	817.2M
Deferred Long Term Liab	24.9M	29.3M	6.9M	59.5M	68.4M	71.8M
Net Invested Capital	230.6M	295.9M	239.6M	142.0M	152.6M	183.2M
Net Working Capital	194.6M	261.9M	205.0M	173.6M	195.2M	172.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether MacroGenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MacroGenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Macrogenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Macrogenics Stock:

How To Invest In MacroGenics

Details

Is MacroGenics Stock a good investment?

Details

What is MacroGenics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for MacroGenics Stock analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Transaction History View history of all your transactions and understand their impact on performance
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital

Is MacroGenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. If investors know MacroGenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MacroGenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

0.949

Quarterly Revenue Growth

(0.85)

Return On Assets

(0.36)

Return On Equity

(0.06)

The market value of MacroGenics is measured differently than its book value, which is the value of MacroGenics that is recorded on the company's balance sheet. Investors also form their own opinion of MacroGenics' value that differs from its market value or its book value, called intrinsic value, which is MacroGenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MacroGenics' market value can be influenced by many factors that don't directly affect MacroGenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MacroGenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if MacroGenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MacroGenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MacroGenics Current Deferred Revenue vs Long Term Investments Analysis

Current Deferred Revenue vs Long Term Investments

Current Deferred Revenue vs Long Term Investments Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Long Term Investments

MacroGenics fundamental ratios Correlations

MacroGenics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MacroGenics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for MacroGenics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Total Equity
Cash And Short Term Investments	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Short Term Debt	- 1.0	Other Current Liab
Cash	- 0.93	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Common Stock	- 0.83	Retained Earnings
Common Stock Total Equity	- 0.83	Retained Earnings